D. E. Shaw & Co., Inc. Biocryst Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 315,263 shares of BCRX stock, worth $2.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

315,263

Previous 229,090 37.62%

Holding current value

$2.52 Million

Previous $1.74 Million 36.13%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.03 - $8.43 $605,796 - $726,438	86,173 Added 37.62%	315,263 $2.37 Million
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $780,161 - $1.06 Million	-121,710 Reduced 34.69%	229,090 $1.74 Million
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $1.31 Million - $2.15 Million	316,924 Added 935.54%	350,800 $2.17 Million
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $15,868 - $24,824	3,245 Added 10.59%	33,876 $172,000
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $152,542 - $207,371	30,631 New	30,631 $183,000
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $858,307 - $1.09 Million	-123,320 Reduced 92.22%	10,403 $73,000
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $3.17 Million - $4.73 Million	-399,530 Reduced 74.92%	133,723 $1.12 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $395,997 - $535,538	37,714 Added 7.61%	533,253 $6.12 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $5.35 Million - $7.34 Million	495,539 New	495,539 $6.24 Million
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $4.1 Million - $9.28 Million	-519,050 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $7.09 Million - $12.1 Million	-613,215 Reduced 54.16%	519,050 $8.44 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $1.79 Million - $2.47 Million	159,731 Added 16.42%	1,132,265 $15.7 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $1.42 Million - $1.77 Million	100,008 Added 11.46%	972,534 $14 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $7.71 Million - $14 Million	811,723 Added 1335.0%	872,526 $13.8 Million
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $126,491 - $233,588	17,163 Added 39.33%	60,803 $618,000
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $147,066 - $375,740	43,640 New	43,640 $325,000
Q2 2020 Aug 14, 2020	SELL	$1.9 - $5.61 $69,768 - $205,999	-36,720 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $2.76 Million - $7.08 Million	-1,722,120 Reduced 97.91%	36,720 $73,000
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $161,322 - $350,040	101,461 Added 6.12%	1,758,840 $6.07 Million
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $415,062 - $619,273	166,025 Added 11.13%	1,657,379 $4.75 Million
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $444,237 - $1.4 Million	152,659 Added 11.4%	1,491,354 $5.65 Million
Q1 2019 May 15, 2019	SELL	$7.38 - $9.72 $1.19 Million - $1.56 Million	-160,787 Reduced 10.72%	1,338,695 $10.9 Million
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $1.36 Million - $2 Million	-208,837 Reduced 12.22%	1,499,482 $12.1 Million
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $410,947 - $594,831	74,447 Added 4.56%	1,708,319 $13 Million
Q2 2018 Aug 14, 2018	BUY	$4.6 - $6.52 $3.08 Million - $4.37 Million	669,566 Added 69.44%	1,633,872 $9.36 Million
Q1 2018 May 15, 2018	BUY	$4.35 - $5.82 $108,023 - $144,528	24,833 Added 2.64%	964,306 $4.6 Million
Q4 2017 Feb 14, 2018	SELL	$4.16 - $5.33 $2.3 Million - $2.95 Million	-552,844 Reduced 37.05%	939,473 $4.61 Million
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $6.12 Million - $8.91 Million	1,492,317	1,492,317 $7.82 Million

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

167M

Call Options Held

728K

Put Options Held

989K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.48B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account